Recent studies suggest that the presence of medium-chain acyl-CoA dehydrogenase (ACADM) in exosomes derived from pancreatic cancer cells can be used as a marker for gemcitabine treatment sensitivity. This evidence concerns the gene ACADM and familial pancreatic carcinoma.